Description
GLP-3 – RETA 20 mg — Opti-Gen Peptides
For laboratory research use only.
Not for human use. Not for veterinary use.
Not licensed by the MHRA. Not a medicinal product.
Research-grade synthetic peptide supplied as a 20 mg sealed vial for lawful laboratory research in the UK. Catalogue name on the label: GLP-3 – RETA. Not a food, supplement or medical device. Not for diagnostic or therapeutic use. Must not be administered to people or animals.
Identification
| Catalogue name | GLP-3 – RETA |
| Also listed as | Reta; GLP-3 |
| Research identity | Retatrutide; LY3437943 |
| Supplier | Opti-Gen Peptides |
| Contents | 20 mg per vial |
| CAS | 2381089-83-2 |
| Class | Synthetic triple GIP / GLP-1 / glucagon receptor analogue |
| Intended use | Laboratory / in-vitro research only |
GLP-3 is not an INN. Not semaglutide, tirzepatide or a licensed pen product.
Quality / storage
Only the lot COA applies. Store as a laboratory peptide under institutional SOP. No reconstitution, pen-loading or injection instructions on this page.
Published research context (not product claims)
Retatrutide is described in literature as a triple agonist at GIP, GLP-1 and glucagon receptors. Receptor papers characterise that pharmacology in experimental systems.
Clinical-development publications (including phase-2 work such as Jastreboff et al.) concern investigational drug programmes. They are not authorisation to sell this vial as a medicine.
Shop slang “GLP-3” must not be used as a weight-loss or diabetes claim. There is no UK marketing authorisation.
UK notice
18+. Buyer confirms lawful laboratory research use only and will not use or resell for unauthorised human or animal use.
Reviews
There are no reviews yet.